Dr. Douglas Loe

Leede Financial Inc.

Recent Articles

Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data 03/11/2026

Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy.

Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026" 03/09/2026

Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts.

Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory 03/06/2026

Leede Financial maintains its current rating on CareRx and raised its target price, following FQ425 results showing continued sequential improvement in EBITDA, margins, and operating cash flow.

Biotech Co. Expands Testing Tied to its Cell Pouch Bio-hybrid Organ 01/13/2026

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) seeks to determine how a newly developed immunosuppressive agent and, separately, how a different type of islet will work in conjunction with cell implantation via its proven Cell Pouch Bio-hybrid Organ, noted a Leede Financial Inc. report. Read on to learn more about what this Speculative Buy-rated company is working on.

Data on 2 Drugs, Identified Via AI, Shared at Conference 12/04/2025

Rakovina Therapeutics Inc.'s (RKV:TSX.V) preclinical ATR inhibitors, Compound A and Compound C, exhibit similarities to two clinical-stage drugs in the same class, noted a Leede Financial Inc. report.

Analyst: Scientific Instrument Co.'s Q3/25 Results 'Soft' 12/02/2025

Nanalysis Scientific Corp. (NSCI:TSX.V; NSCIF:OTC; 1N1:FSE) has its price target lowered as a result, but is expected to improve its financials in the near term, noted a Leede Financial Inc. report.

Preclinical Compounds Perform Better Than Existing Drugs 11/13/2025

Rakovina Therapeutics Inc.'s (RKV:TSX.V) AI-designed Compounds A, B and C demonstrated the same ATR blocking activity as three of Big Pharma's existing, clinical-stage drugs but at much lower concentrations, noted a Leede Financial Inc. report.

Seeking Formulation of New Drug, Biopharma Co. Signs LOI 09/05/2025

Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report.

Medical Co.'s New Joint Venture Could Expand Co.'s Footprint 08/13/2025

Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating.

Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment 08/11/2025

Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock.

Canadian Pharma Finds Promising Cardiovascular Breakthrough 08/08/2025

Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) reports headline Phase II data from its 109-patient acute myocarditis study, known as the ARCHER trial. Read to see how one analyst rates the stock.

Pancreas Cancer Becoming Top Focus for Biotech Co.? 07/22/2025

Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) published survival data for the use of its immunotherapy pelareorep in pancreatic cancer, and these support the view that this indication should be primary, noted a Leede Financial Inc. report.

Canadian Biotech Targets Massive Cell Technology Gains 07/10/2025

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently announced a partnership with Eledon Pharmaceuticals Inc. (ELDN:NASDAQ) to explore the utility of Eledon's clinical-stage anti-CD40L monoclonal antibody tegoprubart/AT-1501 for conferring sustainable immune evasion of pancreatic islets deployed into Sernova's Cell Pouch device. Read on to see why one Leede Financial Inc. analyst rates this stock as a Speculative Buy.

Q1/25 Financials of Cancer Drug Developer Released 06/12/2025

Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report.

Analyst Reveals Undervalued Pharmaceutical Gem in Canada 04/14/2025

In a recent research note from Leede Financial Inc. analyst Dr. Douglas Loe said Theratechnologies Inc. (TH:TSX; THTX:NASDAQ) has long term potential.

Biotech Advancing Pivotal Phase III Breast Cancer Trial 03/11/2025

Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc.

FDA OKs Trial of Cell Reservoir in Thyroid Disease 03/10/2025

In this Phase 1 study, post-thyroidectomy patients will be treated with their own thyroid cells via this implantable delivery device, noted a Leede Financial Inc. report.

Canadian Healthcare Co. Showcases Stable FQ424 03/06/2025

Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy.

Kentucky Medical Co. Has Strong Operating Fundamentals 02/12/2025

Quipt Home Medical Corp. (QIPT:NASDAQ; QIPT:TSX.V) received a lowered price target but a Buy rating from a Leede Financial Inc. research note.

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease 02/04/2025

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company.

Medical Equipment Co. Shows Strong Profit Margin 12/20/2024

Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report.

FDA Decision on Drug for Bone Marrow Due Early 2025 12/06/2024

The manufacturer sheds light on the amount and remittance schedule of the cash payment it must remit to its partner if the drug gets approved, noted a Leede Financial Inc. report.

Developer of Medical Instruments Attracts Research Coverage 12/02/2024

Both of this Buy-rated company's two business divisions are contributing to topline growth, noted a Leede Financial Inc. report.

Analyst Says Biotech's Data Supports Advancement Into Phase III 11/19/2024

Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.

Opportunity Arises for Co. With Cell Pouch 11/12/2024

This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.

Medical Co. Ready for a Transformative F2025 11/05/2024

The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates.

Biotech Shares Positive Phase I Data for Alzheimer's Treatment 10/31/2024

Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%.

Co's. Cell Pouch Performs Well in Study 09/16/2024

Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report.

Long Term Care Co.'s Target Price Raised 08/14/2024

Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results.

Biopharma Co. Reports Strong FQ224 Results Driven 07/11/2024

Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX).